Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Sepia Therapeutics Inc. operates a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 2 pending office actions. These matters are distributed across a matching number of distinct examiners and 2 distinct art units, showing a diversified prosecution front despite the small number of active cases.
The busiest examiner for this portfolio is GULLEDGE, BRIAN M, who is responsible for 1 busiest examiner pending office action. This indicates that the workload is split, with the other action assigned to a different examiner. This distribution across multiple distinct examiners means that the company manages different examiner styles and art unit preferences simultaneously.
The involvement of multiple distinct art units suggests that the Biotechnology & Pharmaceuticals applications cover varied technical subjects. With a pair of pending office actions in total, the workload is spread across different examination teams. Practitioners can use the presence of multiple examiners to compare prosecution results within the same corporate portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEVENS, MARK V | 1 | 65.5% | +41.6% |
| GULLEDGE, BRIAN M | 1 | 55.8% | +26.1% |
| HASAN, KHALEDA B | 1 | 59.4% | +49.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17701325 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN B (APOB) GENE EXPRESSION | HASAN, KHALEDA B | 31d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17701325 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN B (APOB) GENE EXPRESSION | HASAN, KHALEDA B | 31d overdue |
| 18867152 | LIPIDS FOR DELIVERY OF THERAPEUTIC AGENTS | STEVENS, MARK V | — |
| 18556563 | TISSUE-SPECIFIC NUCLEIC ACID DELIVERY BY MIXED CATIONIC LIPID PARTICLES | GULLEDGE, BRIAN M | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| 1637 | 1 |
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18867152 | LIPIDS FOR DELIVERY OF THERAPEUTIC AGENTS | STEVENS, MARK V | 1613 | §112 | Non-Final OA | — | Pending | Nov 19, 2024 |
| 18556563 | TISSUE-SPECIFIC NUCLEIC ACID DELIVERY BY MIXED CATIONIC LIPID PARTICLES | GULLEDGE, BRIAN M | 1637 | §103 | Non-Final OA | — | Pending | Oct 20, 2023 |
| 17701325 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN B (APOB) GENE EXPRESSION | HASAN, KHALEDA B | 1636 | §102§103§112 | Final Rejection | 31d overdue | Pending | Mar 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial